Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis.
chemoradiotherapy
conversion surgery
unresectable pancreatic ductal adenocarcinoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Mar 2021
02 Mar 2021
Historique:
received:
01
02
2021
revised:
23
02
2021
accepted:
25
02
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Unresectable pancreatic ductal adenocarcinoma (UR-PDAC) has a poor prognosis. Conversion surgery is considered a promising strategy for improving the prognosis of UR-PDAC. This study aimed to investigate the clinical benefits of conversion surgery in patients with UR-PDAC. We retrospectively evaluated patients with PDAC who were referred to our department for possible surgical resection between January 2006 and December 2019. Conversion surgery was performed only in patients with UR-PDAC who could expect R0 resection. We analyzed the prognostic factors for overall survival among patients who underwent conversion surgery. Overall, 638 patients with advanced pancreatic cancer were enrolled in this study. According to resectability, resectable cancer (R) was present in 180 patients, borderline resectable cancer (BR) was present in 60 patients, unresectable locally advanced cancer (UR-LA) was present in 252 patients, and unresectable cancer with distant metastasis (UR-M) was present in 146 patients. Conversion surgery was performed in 20 of the 398 UR cases (5.1%). The median period between the initial therapy and conversion surgery was 15.5 months. According to the Response Evaluation Criteria in Solid Tumors (RECIST) evaluation, the treatment response was CR in one patient, PR in 13, SD in five, and PD in one. Downstaging was pathologically determined in all cases. According to the Evans grading system, grade I was observed in four patients (20%), grade IIb was observed in seven (35%), III was observed in seven (35%), and IV was observed in two (10%). We compared the overall survival period from initial treatment among patients undergoing conversion surgery; the median overall survival durations in the conversion surgery, R, BR, UR-LA, and UR-M groups were 73.7, 32.7, 22.7, 15.7, and 8.8 months, respectively. Multivariate analysis revealed that the presence or absence of chemoradiotherapy (CRT) and the RECIST partial response (PR)/complete response (CR) for the main tumor were statistically significant prognostic factors for overall survival among patients undergoing conversion surgery ( In UR-PDAC, it is important to perform multidisciplinary treatment, including CRT with conversion surgery.
Sections du résumé
BACKGROUND
BACKGROUND
Unresectable pancreatic ductal adenocarcinoma (UR-PDAC) has a poor prognosis. Conversion surgery is considered a promising strategy for improving the prognosis of UR-PDAC. This study aimed to investigate the clinical benefits of conversion surgery in patients with UR-PDAC.
METHODS
METHODS
We retrospectively evaluated patients with PDAC who were referred to our department for possible surgical resection between January 2006 and December 2019. Conversion surgery was performed only in patients with UR-PDAC who could expect R0 resection. We analyzed the prognostic factors for overall survival among patients who underwent conversion surgery.
RESULTS
RESULTS
Overall, 638 patients with advanced pancreatic cancer were enrolled in this study. According to resectability, resectable cancer (R) was present in 180 patients, borderline resectable cancer (BR) was present in 60 patients, unresectable locally advanced cancer (UR-LA) was present in 252 patients, and unresectable cancer with distant metastasis (UR-M) was present in 146 patients. Conversion surgery was performed in 20 of the 398 UR cases (5.1%). The median period between the initial therapy and conversion surgery was 15.5 months. According to the Response Evaluation Criteria in Solid Tumors (RECIST) evaluation, the treatment response was CR in one patient, PR in 13, SD in five, and PD in one. Downstaging was pathologically determined in all cases. According to the Evans grading system, grade I was observed in four patients (20%), grade IIb was observed in seven (35%), III was observed in seven (35%), and IV was observed in two (10%). We compared the overall survival period from initial treatment among patients undergoing conversion surgery; the median overall survival durations in the conversion surgery, R, BR, UR-LA, and UR-M groups were 73.7, 32.7, 22.7, 15.7, and 8.8 months, respectively. Multivariate analysis revealed that the presence or absence of chemoradiotherapy (CRT) and the RECIST partial response (PR)/complete response (CR) for the main tumor were statistically significant prognostic factors for overall survival among patients undergoing conversion surgery (
CONCLUSION
CONCLUSIONS
In UR-PDAC, it is important to perform multidisciplinary treatment, including CRT with conversion surgery.
Identifiants
pubmed: 33801465
pii: cancers13051057
doi: 10.3390/cancers13051057
pmc: PMC7958855
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Surgery. 2018 Nov;164(5):1049-1056
pubmed: 30068484
Ann Surg Oncol. 2017 Aug;24(8):2397-2403
pubmed: 28516291
Ann Gastroenterol Surg. 2019 Oct 29;4(1):6-13
pubmed: 32021953
Cancer. 2012 Jun 15;118(12):3182-90
pubmed: 22028089
Cancers (Basel). 2019 Feb 26;11(3):
pubmed: 30813624
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
J Hepatobiliary Pancreat Sci. 2012 Mar;19(2):152-8
pubmed: 21647560
J Gastrointest Surg. 2016 Nov;20(11):1830-1835
pubmed: 27604886
Surg Today. 2019 Aug;49(8):670-677
pubmed: 30730003
Front Oncol. 2020 Jan 14;9:1501
pubmed: 31993372
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Mol Clin Oncol. 2017 Jun;6(6):963-967
pubmed: 28588798
Ann Surg. 2019 Apr;269(4):733-740
pubmed: 29227344
Cancers (Basel). 2020 May 31;12(6):
pubmed: 32486418
Arch Surg. 1992 Nov;127(11):1335-9
pubmed: 1359851
Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):437-43
pubmed: 15380577
Surg Today. 2019 Nov;49(11):894-906
pubmed: 30949842
J Hepatobiliary Pancreat Sci. 2018 Jul;25(7):342-350
pubmed: 29797499
J Hepatobiliary Pancreat Sci. 2013 Aug;20(6):590-600
pubmed: 23660962
J Hepatobiliary Pancreat Sci. 2014 Sep;21(9):695-702
pubmed: 24841048
World J Surg. 2020 Aug;44(8):2752-2760
pubmed: 32291503
JAMA. 2016 May 3;315(17):1844-53
pubmed: 27139057
Lancet. 2020 Jun 27;395(10242):2008-2020
pubmed: 32593337
Surgery. 2004 Nov;136(5):1003-11
pubmed: 15523393
PLoS Med. 2010 Apr 20;7(4):e1000267
pubmed: 20422030
Ann Surg. 2015 Jan;261(1):12-7
pubmed: 25599322
Medicine (Baltimore). 2018 Dec;97(50):e13592
pubmed: 30558029
Br J Radiol. 2017 Jul;90(1075):20170165
pubmed: 28590776
Lancet. 2016 Jul 16;388(10041):248-57
pubmed: 27265347
Ann Surg Oncol. 2005 Mar;12(3):214-21
pubmed: 15827813
Ann Surg. 2016 Sep;264(3):457-63
pubmed: 27355262
Lancet. 2011 Aug 13;378(9791):607-20
pubmed: 21620466
Pancreatology. 2020 Jan;20(1):89-94
pubmed: 31787525
J Hepatobiliary Pancreat Sci. 2011 Sep;18(5):712-6
pubmed: 21455748
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1212-20
pubmed: 26350368
Ann Surg. 2021 Jan 1;273(1):154-162
pubmed: 30921051
J Hepatobiliary Pancreat Sci. 2018 May;25(5):261-268
pubmed: 29651809
J Gastrointest Surg. 2017 Nov;21(11):1793-1803
pubmed: 28849366
Eur J Surg Oncol. 2019 Aug;45(8):1453-1459
pubmed: 30981446
Ann Surg. 2018 Aug;268(2):215-222
pubmed: 29462005
Ann Gastroenterol Surg. 2019 Jul 09;3(5):523-533
pubmed: 31549012